Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.57 |
| ▸ | CTSK | P43235 | 5/20 | 0.57 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.44 |
| ▸ | CPN1 | P15169 | 1/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23850037 | 1.00 | CTSS (0.57) | CTSSCTSKIDO1AAK1CPN1 | |
| SCHEMBL375943 | 1.00 | CTSS (0.57) | CTSSCTSKIDO1AAK1CPN1 | |
| Hydrochloric Acid SCHEMBL31407550 | 0.99 | CTSS (0.56) | CTSSCTSKIDO1AAK1CPN1 | |
| Acetic Acid SCHEMBL27622126 | 0.97 | CTSS (0.55) | CTSSCTSKIDO1AAK1CPN1 | |
| Acetic Acid SCHEMBL3162997 | 0.97 | CTSS (0.55) | CTSSCTSKIDO1AAK1CPN1 | |
| SCHEMBL1351322 | 0.90 | CTSS (0.68) | CTSSCTSKIDO1AAK1KMT2A | |
| SCHEMBL956167 | 0.90 | CTSS (0.68) | CTSSCTSKIDO1AAK1KMT2A | |
| SCHEMBL956164 | 0.90 | CTSS (0.68) | CTSSCTSKIDO1AAK1KMT2A | |
| SCHEMBL17373551 | 0.88 | CTSS (0.53) | CTSSCTSKIDO1AAK1KMT2A | |
| SCHEMBL6386727 | 0.88 | CTSS (0.53) | CTSSCTSKIDO1AAK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737470-A2 | C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | Zikani Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12552825-B2 | C10-alkylene substituted 13-membered macrolides and uses thereof | Zikani Therapeutics , Inc. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-3883647-B1 | C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | ZIKANI THERAPEUTICS INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20240277747-A1 | Compounds for Treating Genetic Diseases | ZIKANI THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4358970-A1 | COMPOUNDS FOR TREATING GENETIC DISEASES | Zikani Therapeutics, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-117836270-A | USP30 inhibitors and uses thereof | 文森雷生物科学股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| EP-4305021-A1 | USP30 INHIBITORS AND USES THEREOF | Vincere Biosciences, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20230093692-A1 | C10-Alkylene Substituted 13-Membered Macrolides and Uses Thereof | ZIKANI THERAPEUTICS, INC. | 2023-03-23 | — | — | US | disclosed |
| WO-2022251730-A1 | COMPOUNDS FOR TREATING GENETIC DISEASES | ZIKANI THERAPEUTICS, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| CN-113573779-A | C10-alkylene substituted 13-membered macrolides and their use | 齐卡尼治疗股份有限公司 | 2021-10-29 | — | — | CN | disclosed |
| EP-3883647-A1 | C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | Zikani Therapeutics, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20150232420-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | EVOTEC (UK) LTD. (GB) | 2015-08-20 | — | — | US | disclosed |
| EP-2079743-B1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| US-20100216802-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2010-08-26 | — | — | US | disclosed |
| CN-1990469-A | Pyrrolidines as dipeptidyl peptidase inhibitors | SMITHKLINE BEECHAM CORP (US) | 2007-07-04 | — | — | CN | disclosed |
| CN-1990468-A | Pyrrolidines as dipeptidyl peptidase inhibitors | SMITHKLINE BEECHAM CORP (US) | 2007-07-04 | — | — | CN | disclosed |
| CN-1723196-A | Fluoropyrrolidines as dipeptidyl peptidase inhibitors | SMITHKLINE BEECHAM CORP (US) | 2006-01-18 | — | — | CN | disclosed |
| WO-1991015507-A1 | PHOSPHONOPEPTIDES WITH COLLAGENASE INHIBITING ACTIVITY | BEECHAM GROUP PLC (GB) | 1991-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277747-A1 | Compounds for Treating Genetic Diseases | UPF1, RRP1B, REV1 | CTSS 3394/4885CTSK 3287/4885IDO1 4855/4885 |
| US-12552825-B2 | C10-alkylene substituted 13-membered macrolides and uses thereof | MALT1, NR3C2, MRPL21 | CTSS 3364/4885CTSK 2147/4885IDO1 3266/4885 |
| US-20150232420-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | HTT, TGM2, GRN | CTSS 498/4885CTSK 874/4885IDO1 1748/4885 |
| US-20230093692-A1 | C10-Alkylene Substituted 13-Membered Macrolides and Uses Thereof | RPS14, RPL17, RPN2 | CTSS 2330/4885CTSK 670/4885IDO1 4309/4885 |
| US-20100216802-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | PLK2, PLK4, PLK3 | CTSS 2866/4885CTSK 983/4885IDO1 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.